Evidence for the impact of obesity on outcomes for bladder cancer have been conflicting and require further study.
Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.
This latest approval now makes enzalutamide the only FDA-approved oral medication indicated for both metastatic and nonmetastatic castration-resistant prostate cancer.
Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.
Current guidelines recommend that patients with bladder cancer undergo radical cystectomy, but concerns with morbidity and mortality have led to a reemergence of trimodal "bladder-sparing" therapy.
According to experts, PARP inhibition, radiopharmaceuticals, and immunotherapy could revolutionize how prostate cancer is treated in the coming decade.
Treatment with enzalutamide decreased the risk of metastasis or death by 71% in patients diagnosed with nonmetastatic castration-resistant prostate cancer.
Though early-stage bladder cancer is infrequently fatal, the decrease in recurrence rates has a meaningful impact on the quality of life for patients as well as treatment costs.
Atezolizumab and pembrolizumab were FDA-approved for the treatment of urothelial carcinoma in 2016 and 2017, respectively.
New findings bolster the case for the predictive utility of ARID1A mutations.
Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage DiagnosisJune 19, 2018
A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.
Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for InhibitionJune 18, 2018
Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.
Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.
In a phase 3 trial, Prostvac-V/F did not significantly prolong overall survival among men with asymptomatic or minimally symptomatic mCRPC.
Abiraterone plus leuprolide compared with leuprolide decreased the risk of biochemical recurrence by 38%.
Steven E. Benner, MD, discusses the updated analysis at the ASCO 2018 meeting in Chicago.
Enzalutamide decreases the risk of clinically meaningful deterioration in HRQoL compared with placebo in men with non-metastatic CRPC, new study finds.
Previous early-phase clinical studies have demonstrated that BGJ398 was active and well tolerated in a variety of FGFR-altered cancers.
Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.
Many patients are cured of all disease (pT0) post-chemotherapy and may be able to defer invasive surgery if properly identified.
Postresection intravesical instillation of gemcitabine decreases non-muscle-invasive urothelial cancer recurrenceMay 22, 2018
In this randomized controlled trial, instilling postresection chemotherapy, specifically gemcitabine, was found to decrease tumor recurrence in non-muscle-invasive urothelial cancer when compared to saline treatment as a placebo.
A study found that bladder cancer and UTUC occurred in 122.22 and 113.97 per 100,000 persons per year, respectively, among kidney transplant recipients.
While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.
Various aspects of optimal treatment, such as optimal dose, drug combination, number of cycles, and duration of therapy have yet to be clearly defined for patients with bladder cancer.
A recent article is only the latest in a series of studies drawing attention to the importance of diet in prostate cancer development.
The BMH online survey allows patients to enter comorbidity data at home prior to consultation.
Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.
Get the latest treatment regimens for testicular cancer, including options such as carboplatin, EP + cisplatin, BEP, and VIP.
Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.
One instance of grade 3 alanine aminotransferase elevation and 5 instances of reversible immune-related adverse events were observed.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- FDA Approves Ivosidenib for IDH1-Mutated Relapsed/Refractory Acute Myeloid Leukemia
- Clinical Stage at First Response May Predict Outcomes in Chronic Lymphocytic Leukemia
- Exercise and Cancer
- Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer
- Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer